Literature DB >> 25045879

Type I and type II Fc receptors regulate innate and adaptive immunity.

Andrew Pincetic1, Stylianos Bournazos1, David J DiLillo1, Jad Maamary2, Taia T Wang2, Rony Dahan2, Benjamin-Maximillian Fiebiger2, Jeffrey V Ravetch2.   

Abstract

Antibodies produced in response to a foreign antigen are characterized by polyclonality, not only in the diverse epitopes to which their variable domains bind but also in the various effector molecules to which their constant regions (Fc domains) engage. Thus, the antibody's Fc domain mediates diverse effector activities by engaging two distinct classes of Fc receptors (type I and type II) on the basis of the two dominant conformational states that the Fc domain may adopt. These conformational states are regulated by the differences among antibody subclasses in their amino acid sequence and by the complex, biantennary Fc-associated N-linked glycan. Here we discuss the diverse downstream proinflammatory, anti-inflammatory and immunomodulatory consequences of the engagement of type I and type II Fc receptors in the context of infectious, autoimmune, and neoplastic disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25045879     DOI: 10.1038/ni.2939

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  104 in total

1.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

2.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

3.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 4.  Human B cell subsets.

Authors:  Stephen M Jackson; Patrick C Wilson; Judith A James; J Donald Capra
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

Review 5.  Inhibitory ITAMs as novel regulators of immunity.

Authors:  Ulrich Blank; Pierre Launay; Marc Benhamou; Renato C Monteiro
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

6.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Authors:  Nicholas S Wilson; Becky Yang; Annie Yang; Stefanie Loeser; Scot Marsters; David Lawrence; Yun Li; Robert Pitti; Klara Totpal; Sharon Yee; Sarajane Ross; Jean-Michel Vernes; Yanmei Lu; Cam Adams; Rienk Offringa; Bob Kelley; Sarah Hymowitz; Dylan Daniel; Gloria Meng; Avi Ashkenazi
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

7.  Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

Authors:  Thomas F Tedder; Aris Baras; Yan Xiu
Journal:  Springer Semin Immunopathol       Date:  2006-11-08

8.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

Review 9.  The coordination of signaling during Fc receptor-mediated phagocytosis.

Authors:  Joel A Swanson; Adam D Hoppe
Journal:  J Leukoc Biol       Date:  2004-10-05       Impact factor: 4.962

10.  DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease.

Authors:  Michael A Portman; Howard W Wiener; Miriam Silva; Aditi Shendre; Sadeep Shrestha
Journal:  Pediatr Rheumatol Online J       Date:  2013-09-05       Impact factor: 3.054

View more
  187 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 3.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

4.  Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.

Authors:  Benjamin M Fiebiger; Jad Maamary; Andrew Pincetic; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

Review 5.  The multiple pathways to autoimmunity.

Authors:  Argyrios N Theofilopoulos; Dwight H Kono; Roberto Baccala
Journal:  Nat Immunol       Date:  2017-06-20       Impact factor: 25.606

6.  VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.

Authors:  Sabrina Ceeraz; Susan K Eszterhas; Petra A Sergent; David A Armstrong; Alix Ashare; Thomas Broughton; Li Wang; Dov Pechenick; Christopher M Burns; Randolph J Noelle; Matthew P Vincenti; Roy A Fava
Journal:  Arthritis Res Ther       Date:  2017-12-08       Impact factor: 5.156

7.  Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions.

Authors:  Alexandra Epp; Juliane Hobusch; Yannic C Bartsch; Janina Petry; Gina-Maria Lilienthal; Carolien A M Koeleman; Simon Eschweiler; Christian Möbs; Ashley Hall; Suzanne C Morris; Dominique Braumann; Christine Engellenner; Josephine Bitterling; Johann Rahmöller; Alexei Leliavski; Robina Thurmann; Mattias Collin; Kelley W Moremen; Richard T Strait; Véronique Blanchard; Arnd Petersen; Timo Gemoll; Jens K Habermann; Frank Petersen; Andreas Nandy; Helga Kahlert; Michael Hertl; Manfred Wuhrer; Wolfgang Pfützner; Uta Jappe; Fred D Finkelman; Marc Ehlers
Journal:  J Allergy Clin Immunol       Date:  2017-07-18       Impact factor: 10.793

Review 8.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

9.  A Functional Role for Antibodies in Tuberculosis.

Authors:  Lenette L Lu; Amy W Chung; Tracy R Rosebrock; Musie Ghebremichael; Wen Han Yu; Patricia S Grace; Matthew K Schoen; Fikadu Tafesse; Constance Martin; Vivian Leung; Alison E Mahan; Magdalena Sips; Manu P Kumar; Jacquelynne Tedesco; Hannah Robinson; Elizabeth Tkachenko; Monia Draghi; Katherine J Freedberg; Hendrik Streeck; Todd J Suscovich; Douglas A Lauffenburger; Blanca I Restrepo; Cheryl Day; Sarah M Fortune; Galit Alter
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

Review 10.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.